Goldman Sachs
AUPH icon

Goldman Sachs’s Aurinia Pharmaceuticals AUPH Stock Holding History

Goldman Sachs’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-155,000
Closed -$1.14M – 6757
2017
Q1 		$1.14M Buy
+155,000
New +$716K ﹤0.01% 4255

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs's AUPH Position: Q2 2026 in Review

Goldman Sachs increased its Aurinia Pharmaceuticals (AUPH) stake by 292% in Q2 2026, buying an estimated $66.9M and bringing the position to 5,619,401 shares worth $95.4M. The position accounts for 0.01% of the portfolio, ranked #1251.

Goldman Sachs first reported a position in AUPH in Q1 2016 and has held it in 41 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Goldman Sachs held 5,619,401 shares of Aurinia Pharmaceuticals worth $95.4M as of Q2 2026.
  • Goldman Sachs bought 4,185,893 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $66.9M.
  • Aurinia Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1251 holding.
  • Goldman Sachs first reported a position in Aurinia Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.